The majority of COVID-19-infected patients who are admitted to the hospital are elderly. Age and the comorbidities that come with it are linked to worsening the disease’s prognosis.
The immune response in older adults is slower, less coordinated, and less effective. Reduced generation of B and T cells in the bone marrow and thymus and lower activity of mature lymphocytes in secondary lymphoid organs are all impacts of aging on the immune system. As a result, the old do not respond as well to the immunological challenge as the young.
Antibody testing is indispensable for evaluating antibody responses in vaccinated individuals compared to convalescent patients. Among vaccinated individuals, males and individuals aged older than 55 years have developed significantly lower production of antibodies to the Wuhan strain.
Neutralizing antibody responses for the gamma variant were even lower. While studies have shown that vaccination helps reduce mortality among older people, given the emergence of alarming new variants, vaccinated individuals over 55 should have their antibody level frequently checked with antibody testing useful in showing the correct time for vaccination.
More severe or long-term side effects of the COVID-19 vaccines are possible and often seen in older adults because the immune response decreases due to age. After vaccination, difficulty breathing, chest pain, confusion, and loss of speech or movement may occur. In this case, vaccination may be a risk that should be considered for older adults with sufficient antibody levels.
In many countries, including the United Kingdom, the lack of approved specific therapeutic agents to treat coronavirus disease (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has prompted the rapid implementation of convalescent plasma therapy (CPT) trials.
In convalescent donations, substantial titers of neutralizing antibody (nAb) are likely required for effective CPT. The relationship of neutralizing antibody titers to reactivity in a series of enzyme-linked immunosorbent assays (ELISA) targeting the spike (S) protein, the main target of the human immune response, is still being evaluated. At this point, GENZPRO offers an inevitable opportunity for antibody testing.
What is GENZPRO?
The GENZPRO Biochip SARS-CoV-2 IgG Test is a single-use test based on the ELISA on-a-chip technology to measure anti-SARS-CoV-2 IgG antibody levels in human serum plasma or whole blood when used with the GENZPRO equipment, delivering results in 5 minutes.
The level of IgG antibodies can be utilized to detect a prior infection or immunization after vaccination. Regular measurements can be used to track changes in IgG antibody levels and, as a result, for immunization schedules.
GENZPRO Biochip tests have a digital output and recording system that allows for extensive study of each patient or a larger group of patients. Remote data access enables healthcare practitioners to evaluate and track results closely.
GENZPRO, which gives results in 5 minutes after inserting the chip into the device, continues to be one of the best in the industry in precision measurement as well as giving fast results.
For older adults, antibody measurement before and after vaccination is very important for the effective screening of the immune response. At this point, GENZPRO is a ground-breaking solution that helps elderly patients make the right decision about their vaccination schedules, especially with its fast and accurate results.
The way to stay healthy is through regular follow-up and control. We continue to develop, expand and produce for older adults who have difficulty developing immune responses to diseases such as COVID-19. Be aware, stay healthy.